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Abstract
Objectives: The presence of ESBL/AmpC-producing E. coli in cattle has been reported previously, however information on
veal calves is limited. This study describes the prevalence and molecular characteristics of E. coli with non-wild type
susceptibility to cefotaxime in veal calves at slaughter.
Methods: Faecal samples from 100 herds, 10 individual animals per herd, were screened for E. coli with non-wild type
susceptibility for cefotaxime. Molecular characterization of ESBL/AmpC genes and plasmids was performed on one isolate
per herd by microarray, PCR and sequence analysis.
Results: 66% of the herds were positive for E. coli with non-wild type susceptibility for cefotaxime. Within-herd prevalence
varied from zero to 90%. 83% of E. coli producing ESBL/AmpC carried blaCTX-M genes, of which blaCTX-M-1, blaCTX-M-14 and
blaCTX-M-15 were most prevalent. The dominant plasmids were IncI1 and IncF-type plasmids.
Conclusions: A relatively high prevalence of various blaCTX-M producing E. coli was found in veal calves at slaughter. The
genes were mainly located on IncI1 and IncF plasmids.
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Introduction
The development of resistance to extended spectrum cephalo-
sporins (ESC) has evolved rapidly world-wide in both clinical
settings as well as in the community. Resistance to ESC is mainly
caused by various extended spectrum ß-lactamases (ESBL) or
AmpC ß-lactamases (AmpC) that are often found in Enterobacte-
riaceae and hydrolyse the ß-lactam ring of these antibiotics [1].
These enzymes are encoded by genes that are frequently located
on mobile genetic elements (plasmids) [2], which have the ability
to transfer horizontally within and between different bacterial
species. Novel ESBL/AmpC genes or gene variants are reported
on a regular basis (http://www.lahey.org/studies) and are
classified based on either their functional characteristics [3] or
primary structure [4].
Food-producing animals have been suggested as the primary
reservoir of zoonotic foodborne pathogens, including antimicro-
bial resistant bacteria [5]. Faecal carriage of ESBL/AmpC-
producing E. coli in cattle has been reported previously
[6,7,8,9,10]. In addition, a recent study showed that in the period
from 2005 to 2010, resistance to ESC in veal calves was mainly
caused by plasmid mediated beta-lactamases, in contrast to the
years before 2005 (Hordijk et al, submitted for publication).
Furthermore, beef, chicken and pig meat products have also been
found to be positive for ESBL/AmpC-producing bacteria [11],
which may constitute a transmission route to humans. However,
studies are difficult to compare, because isolation methods and
sample sizes vary greatly. When cattle is studied, the type of cattle
included is not always specified. For instance dairy farming is very
different from veal calves by means of housing, life expectation
and exposure to antibiotics. The majority of veal farms maintain
an all-in, all-out system, while dairy farms generally maintain a
closed production system. Almost each individual animal on a veal
calf farm originates from another dairy farm. Furthermore,
compared to dairy cattle, veal calves are more frequently exposed
to antimicrobials [12]. These factors may influence the prevalence
and genetic characteristics of antimicrobial resistance genes in
isolates from these animals. Furthermore, antimicrobial suscepti-
bility data from national surveillance studies have shown that
isolates from veal calves are often multi resistant [12].
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Therefore, the aim of this study was to determine the prevalence
of E. coli with reduced susceptibility to ESC in veal calf herds.
Moreover the ESBL/AmpC genes and plasmids on which they are
located were identified to determine their molecular characteristics
in relation to those found in other food-producing animals and
humans.
Materials and Methods
Sampling design and isolation of Escherichia coli
From January to December 2011, fecal samples from 10
individual veal calves were taken from 100 slaughter batches (1000
samples in total). The samples were taken as part of the Dutch
national control program on antimicrobial resistance by the
Netherlands Food and Consumer Product Safety Authority
(NVWA). All slaughter batches originated from different herds.
To ensure anonymity, the origin of samples was aggregated at
province level. The sampled slaughter batches were equally
distributed over the five slaughter houses in the Netherlands and
the sampling took place equally distributed over the year. All fecal
samples were individually screened for ESC reduced susceptible E.
coli using selective enrichment broth. Fecal swabs were taken from
the colon of the carcass after evisceration and subsequently
transferred to the laboratory and placed in a tube with 1 ml Luria-
Bertani broth (Beckton Dickinson) supplemented with 1 mg/L
cefotaxime (Sigma-Aldrich, Germany) (LB+). LB+ tubes were
incubated aerobically at 37uC for 2062 hours. Subsequently, the
overnight LB+ culture was inoculated on a MacConkey agar plate
(Becton Dickinson), which was supplemented with 1 mg/L
cefotaxime (MC+). All MC+ plates were incubated aerobically at
37uC for 2062 hours. From each MC+ plate showing growth, one
colony typical for E. coli was selected, subcultured on blood agar,
and suspended the next day in 1 ml of buffered peptone water
supplemented with 30% glycerol and stored at 280uC, pending
analysis. All selected E. coli were inoculated in 5 ml Gersbach
medium and incubated at 37uC for 2062 hours for E. coli
confirmation. One droplet of Kovac’s Indole reagent (Merck,
Germany) was added to the Gersbach culture to check for
tryptophan reduction following the requirements for E. coli
identification stated by the European Food Safety Authority
(EFSA) [13]. All indole-positive isolates were considered E. coli.
From all isolates showing growth on MacConkey, one randomly
picked isolate was selected per herd for antimicrobial susceptibility
testing and molecular characterization.
Antimicrobial susceptibility testing
All selected isolates (n = 66) were tested for susceptibility to
antimicrobials by broth micro-dilution according to ISO standard
20776-1:2006 using microtitre trays with a custom made
dehydrated panel of antibiotics (Sensititre, Trek Diagnostic
Systems, Basingstoke, UK). The following antibiotics were
included: ampicillin, cefotaxime, ceftazidime, tetracycline, sulfa-
methoxazole, trimethoprim, ciprofloxacin, nalidixic acid, chlor-
amphenicol, florfenicol, gentamicin, kanamycin, streptomycin and
colistin. All results were interpreted using cut-off values defined for
epidemiological purposes as recommended by the European
Committee on Antimicrobial Susceptibility Testing (EUCAST;
http://mic.eucast.org/Eucast2/), apart from sulfamethoxazole,
for which the clinical break point defined by the Clinical and
Laboratory Standards Institute (CLSI) was used [14]. Values
above these cut-offs and break points were interpreted as resistant
(sulfamethoxazole) or non-wild type (all other antimicrobials) [15].
Characterization of ESBL/AmpC genes and plasmids
All selected isolates were screened for ESBL/AmpC genes using
the tube based amr-ve-05 microarray (Alere, Tilburg, the Nether-
lands) [16]. Beta-lactamase gene families identified by this
microarray were subsequently characterized by PCR and
sequence analysis as described previously [17]. For sequence
analysis the following additional primers were used: TEM-Fseq:
59-GCCAACTTACTTCTGACAACG, CMY-F-838: 59-
TGGCGTATTGGCGATATGTA and CMY-R-857: 59-TACA-
TATCGCCAATACGCCA. Primers and conditions used to
identify and sequence the modified aminoglycoside resistance
gene aac(69)Ib-cr have been described previously [18]. Plasmids
were isolated using a modified miniprep method as follows. One
colony of interest was inoculated in 3 ml LB broth and incubated
overnight. Subsequently 1.5 ml of the culture was transferred and
spinned down at 14000 rpm for 5 minutes. The pellet was
suspended in 60 ml TEG buffer (25 mM Tris/Hcl; 10 mM EDTA;
50 mM glucose). Then, 120 ml NaOH/SDS (0.2 M/1%) was
added and the whole sample was placed on ice for 5 minutes.
Subsequently, 90 ml NaOH (3 M) was added and the sample was
placed on ice for 5 minutes. The suspension was spinned down at
14000 rpm for 5 minutes. The supernatant was transferred and
270 ml LiCl (5 M) was added. After 10 minutes, the suspension
was spinned down at 14000 rpm for 5 minutes. The supernatant
was transferred and 1 ml of EtOH (96%) was added. The
suspension was spinned down at 14000 rpm for 10 minutes and
the pellet was resuspended in 200 ml EtOH (70%). The suspension
was spinned down at 13000 rpm for 10 minutes and the pellet was
resuspended in 20 ml H2O. Plasmids were transformed into
Electromax DH10B cells by electroporation (Invitrogen, USA)
by mixing 2 ml of plasmid DNA suspension with 20 ml competent
cells. The cells were electroporated under the following conditions:
1.25 kV, 200 ohm, 25 mFar. Transformants were subsequently
plated on LB agar plates supplemented with 1 mg/L cefotaxime in
order to selectively isolate transformants with ESBLs carrying
plasmids. PCR-based replicon typing (PBRT) was conducted on
the transformants to identify the replicon type of the plasmid
inside the transformant [19]. Plasmid MLST (pMLST) [20] and
replicon sequence typing (RST) were used to further characterize
IncI1 and IncF plasmids, respectively [21]. Plasmids that were
negative in the PBRT analysis were designated ‘‘not typable’’ (nt).
The size of these plasmids was determined by PFGE with S1-
nuclease digestion as described previously [22]. Because this study
focused on plasmid mediated genes, another ESBL/AmpC
suspected isolate from the same herd was included as a
replacement if the micro array results were negative. For isolates
in which no plasmid mediated ESBL/AmpC gene was detected,
the promoter region of the chromosomal ampC gene was
sequenced using primers that have been described previously
[23]. Specific ampC-types were designated as described by Mulvey
et al [24]. In addition a combination disk test was performed as
described previously on all isolates that were negative in the array
[17].
Ethics Statement
Samples were taken from the colon of the veal calves after
slaughter as part of the Dutch national control program on
antimicrobial resistance as required by the zoonosis directive of the
European Parliament (2003/99/EC). Since the sampling of calves
was not performed on live animals, no approval from the ethical
committee was required. In line with ‘Regulation (EC) No 854/
2004 of the European Parliament and of the Council, article 4
section 8’, concerning specific rules for the organisation of official
controls on products of animal origin intended for human
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consumption, the NVWA is the designated authority in the
Netherlands to take samples for surveillance purposes. The
NVWA granted permission to analyse the samples as described
in this paper.
Results
Prevalence of non-wild type cefotaxime susceptible E.
coli
From the 100 herds that were screened for the presence of E. coli
with non-wild type susceptibility at slaughter, 66% were found
positive for E. coli with non-wild type susceptibility to cefotaxime.
The within-herd prevalence of E. coli with non-wild type
susceptibility varied greatly, ranging from zero to 90%. However,
in the majority of the positive farms, less than five out of ten fecal
samples harbored E. coli with non-wild type cefotaxime suscepti-
bility. From all positive farms 90% was located in the eastern and
southern provinces. This is also where veal farming is concentrat-
ed. In addition, 86% of the ESBL/AmpC-producing E. coli was
multi-drug resistant, showing non-wild type susceptibility to three
or more antimicrobial classes, including ß-lactams (Tables 1 and
2).
Of all selected isolates with a non-wild type susceptibility to
cefotaxime, 83% carried genes belonging to the blaCTX-M gene
family (Table 1+2). The predominant genes within this blaCTX-M
group, were blaCTX-M-1 (45.5%), blaCTX-M-14 (16.4%), and blaCTX-
M-15 (21.8%). One of the isolates harbouring blaCTX-M-1 also
harboured blaTEM-52c. The remaining blaCTX-M variants were
blaCTX-M-2/97 (5.5%), blaCTX-M-3 (3.6%) and blaCTX-M-32 (7.2%).
From 11 isolates (17%) that did not harbour blaCTX-M, three
harboured blaTEM-52c (4.5%), and one blaCMY-2 (1.5%). In 6
isolates (9%), only mutations in the promoter region of the
chromosomal ampC were detected. Finally, in one isolate (1.5%)
neither plasmid mediated ESBL/AmpC genes nor mutations in
the promoter region of the chromosomal ampC were detected. This
isolate only harboured the ß-lactamases blaTEM-1c and blaOXA-1.
The predominant plasmid types among all isolates harbouring
ESBL/AmpC genes were IncI1 and IncF. Both IncI1 and IncF
plasmids were present in 26% of the isolates depicted in Tables 1
and 2. The highest diversity of plasmids was observed among
blaCTX-M-1 positive isolates, which was also the most abundant
ESBL variant. In 9 isolates, blaCTX-M-1 was located on IncI1 with
six different IncI1 pMLST types (Table 1). From these six different
pMLST types, four types had not yet been reported in the pMLST
database (http://www.pubmlst.org/plasmid, last accessed: 20
March 2013). Furthermore, in 7 isolates blaCTX-M-1 was located
on IncF plasmids with four different IncF RST profiles. From
these four different profiles, two had not yet been reported in the
pMLST database. The remaining blaCTX-M-1 genes were located
on IncB/O (three isolates), IncN (three isolates) and IncK (one
isolate). In two isolates the plasmid was not typable. The second
largest group of ESBL genes, blaCTX-M-15, was predominantly
carried on IncF plasmids, of which four different RST types were
found among seven isolates (Table 1). From these seven isolates,
five also harboured blaOXA-1 and aac(69)Ib-cr. The remaining
blaCTX-M-15 genes were located on IncI1 (two isolates), IncHI2
(one isolate) and two on not typable plasmids. The blaCTX-M-14
genes were mainly carried on IncK plasmids (Table 2), but also on
IncI1, of which all three plasmids had the same pMLST sequence
type (ST80), and one on IncF (F2; A-; B-)). From the isolates
harbouring blaCTX-M-2/97 or blaCTX-M-3, all genes were located on
different plasmids (Table 1+2). All plasmids carrying blaCTX-M-32,
were not typable. Furthermore, four isolates harboured blaTEM-52c,
of which three were carried on IncI1 plasmids with two different
pMLST types (ST10 and ST36), both belonging to the same
clonal complex (CC5) (Table 2). From the fourth blaTEM-52c, which
was found in an isolate also harbouring blaCTX-M-1, transformation
of the plasmid failed, so no replicon type was established. In the
single isolate harbouring an ampC gene, blaCMY-2 was located on an
IncK plasmid (Table 2). Finally, one transformant harbouring
blaCTX-M-2 showed two replicon types, namely IncP and IncHI2
(Table 2).
Discussion
This study showed that 66% of the slaughter batches of veal
calves were positive for fecal carriage E. coli with a non-wild type
susceptibility to cefotaxime. In 68% of the positive herds, five or
less animals out of ten were found carrier of these isolates. Since
only one isolate per herd was included in the molecular analysis,
no conclusions can be drawn towards clonal diversity of ESBL/
AmpC genes and plasmids in herds with multiple positive animals.
Further in depth studies should be performed to assess whether a
clonal spread within herds or a high diversity of ESBL/AmpC
genes and/or plasmids exists within these herds. Factors that may
influence the prevalence and spread of these resistance determi-
nants within herds, including the use of antimicrobials and farm
management, should be taken into account to analyze possible
differences between farms.
Studies have been performed on fecal carriage of ESBL/AmpC-
producing E. coli in cattle at slaughter in several countries, and the
prevalence varied greatly. In Poland no ESBL/AmpC-producing
E. coli were observed [25], in contrast to France (5.8%) [10],
Switzerland (16%) [26], Hong Kong (3.1%) [27] and Japan
(31.3%) [28]. However, while all studies were performed on
individual animals, comparing these prevalence data should be
performed with care since not all studies used the same selection
methods (e.g. the use of enrichment broth and/or different selective
media), which may have resulted in different screening sensitivities.
The vast majority of plasmid mediated ESBL/AmpC genes in
the present study belonged to the blaCTX-M gene family, of which
blaCTX-M-1 was most abundant, followed by blaCTX-M-15 and
blaCTX-M-14 (Table 1+2). These findings are in line with the
observed trend in the last five years of a retrospective study
performed on faecal samples from veal calves collected at farms
from 1997 to 2010 [29]. Studies from other countries, that focused
on ESBLs in general or blaCTX-M genes in specific, confirm the
relatively high abundance of blaCTX-M-1, blaCTX-M-14 and/or
blaCTX-M-15 genes in either healthy or sick cattle [6,8,10,30]. In
contrast, in the United States, blaCMY-2 is the predominant gene
found in cattle and blaTEM ESBL genes were found at a low level
[31,32]. Furthermore, a study from Hong Kong reported that
blaCTX-M-13 was the only ESBL observed in cattle at slaughter [27]
and blaCTX-M-2 was reported to be predominant in cattle in Japan
[33]. This indicates that there are geographical differences in the
prevalence of resistance genes.
This study showed that ESBL/AmpC genes found in veal calves
were predominantly located on IncI1 and IncF plasmids. These
plasmids belong to the most commonly reported plasmid families
in Enterobacteriaceae [34]. Interestingly, a relatively high proportion
of IncI1 and IncF plasmid subtypes (mainly associated with
blaCTX-M-1) had not yet reported in the pMLST database (Table 1).
IncI1 sequence types (ST) in combination with blaCTX-M-1 have
been reported either commonly (CC3, ST7) or occasionally (ST58)
[34,35,36]. To our knowledge, the combination of blaCTX-M-1 with
IncF type plasmids has not been reported previously. The IncF
RST-type found in this study (F2;A-;B-) has frequently been
associated with blaCTX-M-15 [34,37]. Furthermore, we have also
ESBL/AmpC in E. coli from Veal Calves at Slaughter
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Table 1. E. coli carrying blaCTX-M group 1 genes with their corresponding plasmids and resistance profile.
Plasmid
ESBL Strain Other ß-lactamase Replicon
incI1 pMLST/
incF RST 1, 2 Non-wild type susceptibility3
CTX-M-01 OT-ESBL-0199 TEM-1a, OXA-1 inc nt (97 kb)5 Amp-Ctx-Caz-Tet-Chl-Str-Kan




OT-ESBL-0054 incF F2; A-; B- Amp-Ctx-Caz-Tet-Smx-Ffn-Chl-Gen-Str
OT-ESBL-0198 incF F2; A-; B- Amp-Ctx-Caz-Tet- Gen-Str
OT-ESBL-0591 incF F2; A-; B- Amp-Ctx-Caz-Tet-Ffn-Chl-Str
OT-ESBL-0600 incF F17*; A-; B- Amp-Ctx-Caz-Tet-Gen
OT-ESBL-0382 incF F13#; A-; B20# Amp-Ctx-Caz-Tet-Smx-Str-Kan
OT-ESBL-0519 incF F35#; A-; B- Amp-Ctx-Caz-Tet
OT-ESBL-0565 incF F35#; A-; B_ Amp-Ctx-Caz-Tet
OT-ESBL-0328 incI1 ST3; CC 3 Amp-Ctx-Caz-Smx-tmp
OT-ESBL-0359 incI1 ST3; CC 3 Amp-Ctx-Caz-Tet-Smx-Tmp-Str
OT-ESBL-0406 incI1 ST58; CC 58 Amp-Ctx-Caz-Tet-Smx-Str-Kan
OT-ESBL-0018 incI1 ST58; CC 58 Amp-Ctx-Caz-Tet-Smx-Tmp-Str
OT-ESBL-0062 incI1 new; 1 2 8# 3 3 Amp-Ctx-Caz-Tet-Cip-Nal-Chl-Str
OT-ESBL-0441 incI1 new; 1 5* 17 1 7 Amp-Ctx-Caz-Tet-Str
OT-ESBL-0450 incI1 new; 1 5ˆ16 1 7 Amp-Ctx-Caz-Tet-Smx-Cip-Nal-Chl-Str
OT-ESBL-0477 incI1 new; 1 9# 17 1 7 Amp-Ctx-Caz
OT-ESBL-0546 incK Amp-Ctx-Caz-Tet-Smx-Cip-Nal-Chl-Str-Col
OT-ESBL-0262 OXA-1 incN Amp-Ctx-Caz-Tet-Smx-Tmp-cip-Nal-Ffn-Chl-Str-Kan
OT-ESBL-0361 TEM-1b incN Amp-Ctx-Caz-Tet-Smx-Ffn-Chl-Str-Kan
OT-ESBL-0434 incN Amp-Ctx-Caz
CTX-M-01 OT-ESBL-0414 incI1 ST58; CC 58 Amp-Ctx-Caz-Tet-Smx-Tmp-Str-Kan
+ TEM-52c unknown (145 kb)5
CTX-M-03 OT-ESBL-0437 TEM-1b incB/O Amp-Ctx-Caz-Tet-Smx-Tmp-Cip-Nal-Gen-Str-Kan
OT-ESBL-0567 incF F35#; A-; B- Amp-Ctx-Caz-Tet-Smx-Tmp-Cip-Nal-Str-Kan
CTX-M-15 OT-ESBL-0327 inc nt (110 kb)5 Amp-Ctx-Caz
OT-ESBL-0502 qnrS4 (other plasmid) inc nt (40 kb)5 Amp-Ctx-Caz-Cip
OT-ESBL-0028 incF F2; A-; B- Amp-Ctx-Caz-Tet-Smx-Tmp-Cip-Nal-Str
OT-ESBL-0031 OXA-1, (aac69-Ib-cr)4 incF F31; A4; B1 Amp-Ctx-Caz-Tet-Cip-Nal-Kan
OT-ESBL-0156 OXA-1, (aac69-Ib-cr)4 incF F31; A4; B1 Amp-Ctx-Caz-Tet-Smx-Tmp-Cip-Nal-Gen-Str-Kan
OT-ESBL-0221 OXA-1, (aac69-Ib-cr)4 incF F31; A4; B1 Amp-Ctx-Caz-Tet-Smx-Tmp-Cip-Nal-Gen-Str-Kan
OT-ESBL-0161 TEM-1b, OXA-1, (aac69-Ib-cr)4 incF F31; A4; B1 Amp-Ctx-Caz-Tet-Smx-Tmp-Cip-Nal-Gen-Str-Kan
OT-ESBL-0563 OXA-1, (aac69-Ib-cr)4 incF F31; A-; B1 Amp-Ctx-Caz-Tet-Smx-Tmp-cip-Nal-Ffn-Chl-Gen-Str-Kan
OT-ESBL-0534 TEM-1b IncF F46; A-; B20 Amp-Ctx-Caz-Tet-Smx-Tmp-cip-Nal-Ffn-Chl-Gen-Str-Col
OT-ESBL 0256 IncI1 ST31; CC 31 Amp-Ctx-Caz-Tet-Smx-Tmp-cip-Nal-Ffn-Chl-Gen-Str-Kan
OT-ESBL-0549 incI1 ST31; CC 31 Amp-Ctx-Caz-Cip-Nal
OT-ESBL-0443 incHI2 Amp-Ctx-Caz-Tet-Smx-Tmp-Cip-Nal-Ffn-Chl-Gen-Kan
CTX-M-32 OT-ESBL-0163 inc nt (40 kb)5 Amp-Ctx-Caz-Tet-Smx-Tmp-Cip-Nal-Chl-Str-Kan
OT-ESBL-0173 inc nt (40 kb)5 Amp-Ctx-Caz-Tet-Smx-Tmp-Cip-Nal-Chl-Str-Kan
OT-ESBL-0449 inc nt (40 kb)5 Amp-Ctx-Caz-Tet-Smx-Tmp-Cip-Nal-Ffn-Chl-Str-Kan
OT-ESBL-0473 inc nt (40 kb)5 Amp-Ctx-Caz-Tet-Smx-Tmp-Cip-Nal-Chl-Str-Kan
1The following deviations were found in IncI1 pMLST types: ESBL-0062: trbA8#: nucleotide 371 T.C; ESBL-0441: ardA5*: 59 G.A, 137 A.T, 271 C.G, 331 C.T; ESBL-
0450: ardA5ˆ: 199 G.A, 271 C.G, 331 C.T; ESBL-0477: ardA9#: 199 G.A/C
2The following deviations were found in IncF RST types: ESBL-0301: FIB-26#: 251 G.T; ESBL-0382: FII-13#: 77 A.G and FIB-20#: 194 G.A, 203 T.C; ESBL-0519/0565/
0567: FII-35#: 22 A.T, 38+39.CG insertion.
3Amp = ampicillin, Ctx = cefotaxime, Caz = ceftazidime, Nal = nalidixic acid, Cip = ciprofloxacin, Ffn = florfenicol, Chl = chloramphenicol, Tet = tetracycline, Smx =
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found blaCTX-M-1 in combination with IncB/O plasmids. This has
also been reported in isolates from humans [38] and horses [11].
The blaCTX-M-1 associated with IncN was previously observed in
human isolates [38,39], poultry [40], and in both porcine isolates
and their farm workers, indicating transmission may occur
between food-producing animals and their care takers [41].
In this study, blaCTX-M-15 was mainly located on IncF plasmids,
a combination that has been reported frequently [34,39,42,43]. In
addition, the combination of blaCTX-M-15 with blaOXA-1 and aac69-
Ib-cr (the latter causing reduced susceptibility to aminoglycosides
and fluoroquinolones), has been reported previously [44]. This
combination was observed in the predominant IncF type found in
this study carrying blaCTX-M-15 (F31;A4;B1). Furthermore, both
the IncF RST types F2;A-B- and F31;A4;B1 and the IncI1
pMLST type ST31 that carry blaCTX-M-15 that were reported in
this study have also been isolated from cattle in France [37]. The
blaCTX-M-14 genes in our study were mainly located on IncK
plasmids. This has also been reported in calves in the UK [45], as
well as in isolates from humans and turkey [46,47]. None of the
plasmids harbouring blaCTX-M-32 were typable by PBRT, making
it difficult to draw any conclusions towards genetic characteristics.
For these isolates, we determined the size of the ESBL harbouring
plasmid. The combination of blaTEM-52 with IncI1 (ST36) has been
reported in cattle in France [48], but both ST36 and ST10 in
combination with blaTEM-52 have also been reported in humans
and poultry isolates [38] and are the most commonly found types
[34]. This shows that various combinations of ESBL/AmpC genes
and plasmids are widely distributed in isolates of both animal and
human origin. The IncHI2/P multi replicon plasmid harboring
blaCTX-M-2 was not confirmed as a multi replicon by Southern blot
hybridization. However, similar IncHI2/P plasmids harboring
blaCTX-M-2 were reported previously and have been confirmed as
multi replicons [49]. Additional experiments such as PFGE, RFLP
or sequence analysis of the whole plasmid are required to
determine whether the plasmids with similar replicon types,
pMLST-type or RST-type are clonally related. Based on the data
presented in this study we cannot determine whether the
overlapping genes and plasmids reside in E. coli that are host
specific (animal or human) or that they proliferate well in both
human and animal hosts.
sulfamethoxazole, Tmp = trimethoprim, Str = streptomycin, Kan = kanamycin, Gen = gentamicin), Col = colistin.
4qnrS and aac(69)Ib-cr are not ß-lactamase genes, but cause reduced susceptibility to quinolones. aac(69)Ib-cr also causes reduced susceptibility to aminoglycosides.
5Plasmid size in kilo bases (kb) of non-typeble plasmids.
doi:10.1371/journal.pone.0065681.t001
Table 2. E. coli carrying ESBL/AmpC genes other than blaCTX-M group 1 with their corresponding plasmids and resistance profile.
Plasmid
ESBL Strain Other ß-lactamase Replicon
incI1 pMLST/incF
RST Non-wild type susceptibility1
CTX-M-02 OT-ESBL-0301 TEM-1b incF F1; A6; B26# Amp-Ctx-Caz-Tet-Smx-Tmp-cip-Nal-Ffn-Chl-Gen-Str-Kan
OT-ESBL-0310 incHI1 Amp-Ctx-Caz-Tet-Smx-Tmp-Ffn-Chl-Gen-Kan
OT-ESBL-0514 incP, incHI2 Amp-Ctx-Caz-Tet-Smx-Tmp-Ffn-Chl-Str-Kan
CTX-M-14 OT-ESBL-0403 incF F2; A-; B- Amp-Ctx-Caz-Tet-Smx-Tmp-cip-Nal-Ffn-Chl-Gen-Str-Kan-Col
OT-ESBL-0021 TEM-1b incI1 ST80 Amp-Ctx-Caz-Tet-Smx-Tmp-Cip-Nal-Ffn-Chl-Str
OT-ESBL-0336 incI1 ST80 Amp-Ctx-Caz-Tet-Smx-Cip-Nal-Ffn-Chl-Str-Kan
OT-ESBL-0337 incI1 ST80 Amp-Ctx-Caz-Tet-Smx-Cip-Nal-Ffn-Chl-Str-Kan
OT-ESBL-0058 incK Amp-Ctx-Caz-Tet-Smx-tmp-Str
OT-ESBL-0291 incK Amp-Ctx-Caz-Tet-Smx-Tmp-Str
OT-ESBL-0380 TEM-1b incK Amp-Ctx-Caz-Tet-Smx-Tmp-cip-Nal-Ffn-Chl-Gen-Str-Kan
OT-ESBL-0405 incK Amp-Ctx-Caz-Tet-Gen
OT-ESBL-0590 incK Amp-Ctx-Caz-Tet-Smx-Tmp-Cip-Nal-Chl-Gen-Str
TEM-52c OT-ESBL-0192 incI1 ST36; CC 5 Amp-Ctx-Caz
OT-ESBL-0364 incI1 ST36; CC 5 Amp-Ctx-Caz-Smx-tmp-Cip-Nal-Chl-Str
OT-ESBL-0392 TEM-1b incI1 ST10; CC 5 Amp-Ctx-Caz-Tet-Smx-Tmp-Chl-Str
CMY-2 OT-ESBL-0357 incK Amp-Ctx-Caz-Tet-Str
ampC-type-3 OT-ESBL-0281 - Amp-Ctx-Caz-Tet-Smx-Str-Kan
OT-ESBL-0386 TEM-1b - Amp-Ctx-Caz-Tet-Smx-Ffn-Chl-Str
OT-ESBL-0453 - Amp-Ctx-Caz
OT-ESBL-0599 TEM-1a - Amp-Ctx-Caz-Tet-Smx-Tmp-Str-Kan
OT-ESBL-0601 TEM-1b - Amp-Ctx-Caz-Tet-Smx-Ffn-Chl-Str
ampC-type-11var OT-ESBL-0543 TEM-1a - Amp-Ctx-Caz-Tet-Smx-Tmp-Str
Unknown OT-ESBL-0261 TEM-1c, OXA-1, ampc WT - Amp-Ctx-Caz-Tet-Smx-Tmp-cip-Nal-Ffn-Chl-Str-Col
1Amp = ampicillin, Ctx = cefotaxime, Caz = ceftazidime, Nal = nalidixic acid, Cip = ciprofloxacin, Ffn = florfenicol, Chl = chloramphenicol, Tet = tetracycline, Smx =
sulfamethoxazole, Tmp = trimethoprim, Str = streptomycin, Kan = kanamycin, Gen = gentamicin), Col = colistin.
doi:10.1371/journal.pone.0065681.t002
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In six herds, only promoter mutations of the chromosomal ampC
gene were detected (Table 2) and no isolates harbouring plasmid
mediated ESBL/AmpC genes were found within the same herd.
Since this study focused on the dissemination of plasmid mediated
ESBL/AmpC genes, this prevalence is likely to be an underesti-
mate of the actual number of herds that are positive for
chromosomal ampC genes with promoter variations that lead to
non-wild type susceptibility to cefotaxime. Furthermore, we based
the absence of plasmid mediated ESBL/AmpC genes on array
data. Novel genes or ESBL/AmpC variants not present on the
array will have been missed. The phenotypic combination disk test
was performed on all isolates negative in the array in order to
reduce the chance of missing novel genes.
The fact that international trafficking of live calves from many
different dairy farms to Dutch veal calf farms happens on a large
scale may contribute to the high dissemination observed in this
study. This may also explain the high diversity in gene/plasmid
combinations compared to Dutch poultry, in which blaCTX-M-1 is
highly prevalent and commonly associated with IncI1 [36].
Conclusion
A relatively high percentage of slaughter batches (66%) were
found positive for E. coli with a non-wild type susceptibility to
cefotaxime. The within-herd prevalence varied greatly from zero
to 90% positive. In the majority of herds positive for ESBL/
AmpC-producing E. coli, the within-farm prevalence was below
50%. Furthermore, plasmid mediated resistance to cefotaxime was
predominantly caused by enzymes encoded by the blaCTX-M gene
family. Many gene-plasmid combinations found in this study have
also been found in cattle in other countries, indicating that there is
a non-local dissemination of resistance determinants. However,
since the number of ESBL/AmpC-producing E. coli was not
quantified, no conclusions can be drawn about the actual risk of
presence.
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